General MedicationsSUBCUTANEOUSStandard
ZYCUBO
COPPER HISTIDINATE
Standard Dose
2.9MG/VIAL
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Prescription
Summary
Approval overview ZYCUBO is listed in Drugs@FDA under application 211241 (NDA).
Review priority: PRIORITY Marketing status: Prescription Active ingredient COPPER HISTIDINATE Form and strength POWDER;SUBCUTANEOUS - 2.9MG/VIAL Sponsor SENTYNL THERAPS INC Submission history Latest submission status date: 2026-01-12 00:00:00.
Structured Monograph
Clinical summary
Approval overview ZYCUBO is listed in Drugs@FDA under application 211241 (NDA). Review priority: PRIORITY Marketing status: Prescription Active ingredient COPPER HISTIDINATE Form and strength POWDER;SUBCUTANEOUS - 2.9MG/VIAL Sponsor SENTYNL THERAPS INC Submission history Latest submission status date: 2026-01-12 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Prescription
- • Review priority: PRIORITY
Interaction Notes
- No interaction notes stored yet.